Synopsis
Synopsis
0
KDMF
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Calcihexal
2. Calcimar
3. Calcitonin Salmon
4. Forcaltonin
5. Fortical
6. Miacalcic
7. Miacalcin
8. Recombinant Salmon Calcitonin
9. Salcatonin
10. Salmon Calcitonin (1-32)
11. Synthetic Salmon Calcitonin
1. Calcitonin-salmon
2. Thyrocalcitonin (salmon)
3. Cibacalcin
4. Calcitonina
5. Calcitar
6. Bionocalcin
7. Calcimonta
8. Calcitoran
9. Cibacalcine
10. Eptacalcin
11. Miracalcic
12. Osseocalcina
13. Ostostabil
14. Porostenina
15. Prontocalcin
16. Rulicalcin
17. Salmocalcin
18. Salmotonin
19. Tonocalcin
20. Astronin
21. Biocalcin
22. Calciben
23. Calcinil
24. Calcioton
25. Calogen
26. Calsynar
27. Caltine
28. Catonin
29. Citonina
30. Ipocalcin
31. Kalsimin
32. Oseototal
33. Osteobion
34. Osteovis
35. Ostosalm
36. Quosten
37. Riostin
38. Salcatyn
39. Salmofar
40. Stalcin
41. Staporos
42. Steocin
43. Cadens
44. Casalm
45. Ostora
46. Salcat
47. Ucecal
48. Calco
49. Karil
50. Sical
51. Isi-calcin
52. Calcitonin,salmon
53. Calsynar Lyo L
54. Calcitonin(salmon)
55. Calcitonin, Salmar
56. Salmon Calcitonin I
57. Calcitonin Vom Lachs
58. Calcitonine De Saumon
59. Tz-ct
60. Unii-7sfc6u2vi5
61. Salmon Calcitonin-(i-32)
62. 7sfc6u2vi5
63. Salmon Calcitonin-(1-32)
64. Chebi:3306
65. Calcitonin, Salmon, For Bioassay
66. Dtxsid601026667
67. Calcitonin [usan:inn:ban:jan]
68. Einecs 256-342-8
69. Ncgc00167232-01
70. Calcitonin Salmon, >=97% (hplc), Powder
71. Calcitonin Salmon, European Pharmacopoeia (ep) Reference Standard
72. Calcitonin Salmon, United States Pharmacopeia (usp) Reference Standard
73. Cyclo-[cys-ser-asn-leu-ser-thr-cys]-val-leu-gly-lys-leu-ser-gln-glu-leu-his-lys-leu-gln-thr-tyr-pro-arg-thr-asn-thr-gly-ser-gly-thr-pro-nh2
Molecular Weight | 3431.9 g/mol |
---|---|
Molecular Formula | C145H240N44O48S2 |
XLogP3 | -16.6 |
Hydrogen Bond Donor Count | 52 |
Hydrogen Bond Acceptor Count | 55 |
Rotatable Bond Count | 99 |
Exact Mass | 3430.7166627 g/mol |
Monoisotopic Mass | 3429.7133079 g/mol |
Topological Polar Surface Area | 1560 Ų |
Heavy Atom Count | 239 |
Formal Charge | 0 |
Complexity | 7970 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 34 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.
Calcitonin inhibits bone resorption by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts. This leads to a net increase in bone mass and a reduction in plasma calcium levels. It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption. In consequence, there is an increase in the jejunal secretion of water, sodium, potassium, and chloride.
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Calcium-Regulating Hormones and Agents
Hormones and molecules with calcium-regulating hormone-like actions that modulate OSTEOLYSIS and other extra-skeletal activities to maintain calcium homeostasis. (See all compounds classified as Calcium-Regulating Hormones and Agents.)
Absorption
Salmon calcitonin is rapidly absorbed with bioavailability of 71% following subcutaneous injection and 66% following intramuscular injection in humans. Via the nasal route, the bioavailability varies between 3 to 5% relative to IM.
Route of Elimination
Urine. Studies with injectable calcitonin show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption in the kidney.
Volume of Distribution
0.15 to 0.3 L/kg
Salmon calcitonin primarily undergoes degradation in the kidneys to form pharmacologically inactive metabolites. It is also metabolized in the blood and the peripheral tissue.
Half-life elimination (terminal): I.M. 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes
Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Calcitonin Salmon Recombinant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Calcitonin Salmon Recombinant, including repackagers and relabelers. The FDA regulates Calcitonin Salmon Recombinant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Calcitonin Salmon Recombinant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Calcitonin Salmon Recombinant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Calcitonin Salmon Recombinant supplier is an individual or a company that provides Calcitonin Salmon Recombinant active pharmaceutical ingredient (API) or Calcitonin Salmon Recombinant finished formulations upon request. The Calcitonin Salmon Recombinant suppliers may include Calcitonin Salmon Recombinant API manufacturers, exporters, distributors and traders.
click here to find a list of Calcitonin Salmon Recombinant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Calcitonin Salmon Recombinant DMF (Drug Master File) is a document detailing the whole manufacturing process of Calcitonin Salmon Recombinant active pharmaceutical ingredient (API) in detail. Different forms of Calcitonin Salmon Recombinant DMFs exist exist since differing nations have different regulations, such as Calcitonin Salmon Recombinant USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Calcitonin Salmon Recombinant DMF submitted to regulatory agencies in the US is known as a USDMF. Calcitonin Salmon Recombinant USDMF includes data on Calcitonin Salmon Recombinant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Calcitonin Salmon Recombinant USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Calcitonin Salmon Recombinant suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Calcitonin Salmon Recombinant Drug Master File in Japan (Calcitonin Salmon Recombinant JDMF) empowers Calcitonin Salmon Recombinant API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Calcitonin Salmon Recombinant JDMF during the approval evaluation for pharmaceutical products. At the time of Calcitonin Salmon Recombinant JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Calcitonin Salmon Recombinant suppliers with JDMF on PharmaCompass.
A Calcitonin Salmon Recombinant CEP of the European Pharmacopoeia monograph is often referred to as a Calcitonin Salmon Recombinant Certificate of Suitability (COS). The purpose of a Calcitonin Salmon Recombinant CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Calcitonin Salmon Recombinant EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Calcitonin Salmon Recombinant to their clients by showing that a Calcitonin Salmon Recombinant CEP has been issued for it. The manufacturer submits a Calcitonin Salmon Recombinant CEP (COS) as part of the market authorization procedure, and it takes on the role of a Calcitonin Salmon Recombinant CEP holder for the record. Additionally, the data presented in the Calcitonin Salmon Recombinant CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Calcitonin Salmon Recombinant DMF.
A Calcitonin Salmon Recombinant CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Calcitonin Salmon Recombinant CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Calcitonin Salmon Recombinant suppliers with CEP (COS) on PharmaCompass.
A Calcitonin Salmon Recombinant written confirmation (Calcitonin Salmon Recombinant WC) is an official document issued by a regulatory agency to a Calcitonin Salmon Recombinant manufacturer, verifying that the manufacturing facility of a Calcitonin Salmon Recombinant active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Calcitonin Salmon Recombinant APIs or Calcitonin Salmon Recombinant finished pharmaceutical products to another nation, regulatory agencies frequently require a Calcitonin Salmon Recombinant WC (written confirmation) as part of the regulatory process.
click here to find a list of Calcitonin Salmon Recombinant suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Calcitonin Salmon Recombinant as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Calcitonin Salmon Recombinant API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Calcitonin Salmon Recombinant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Calcitonin Salmon Recombinant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Calcitonin Salmon Recombinant NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Calcitonin Salmon Recombinant suppliers with NDC on PharmaCompass.
Calcitonin Salmon Recombinant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Calcitonin Salmon Recombinant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Calcitonin Salmon Recombinant GMP manufacturer or Calcitonin Salmon Recombinant GMP API supplier for your needs.
A Calcitonin Salmon Recombinant CoA (Certificate of Analysis) is a formal document that attests to Calcitonin Salmon Recombinant's compliance with Calcitonin Salmon Recombinant specifications and serves as a tool for batch-level quality control.
Calcitonin Salmon Recombinant CoA mostly includes findings from lab analyses of a specific batch. For each Calcitonin Salmon Recombinant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Calcitonin Salmon Recombinant may be tested according to a variety of international standards, such as European Pharmacopoeia (Calcitonin Salmon Recombinant EP), Calcitonin Salmon Recombinant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Calcitonin Salmon Recombinant USP).
LOOKING FOR A SUPPLIER?